Codexis (CDXS) Stock Forecast, Price Target & Predictions
CDXS Stock Forecast
Codexis stock forecast is as follows: an average price target of $11.00 (represents a 247.00% upside from CDXS’s last price of $3.17) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
CDXS Price Target
The average price target for Codexis (CDXS) is $11.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $11.00 to $11.00. This represents a potential 247.00% upside from CDXS's last price of $3.17.
CDXS Analyst Ratings
According to 3 Wall Street analysts, Codexis's rating consensus is 'Buy'. The analyst rating breakdown for CDXS stock is 0 'Strong Buy' (0.00%), 2 'Buy' (66.67%), 1 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Codexis Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 30, 2024 | Kristen Kluska | Cantor Fitzgerald | $11.00 | $3.19 | 244.83% | 247.00% |
The latest Codexis stock forecast, released on May 30, 2024 by Kristen Kluska from Cantor Fitzgerald, set a price target of $11.00, which represents a 244.83% increase from the stock price at the time of the forecast ($3.19), and a 247.00% increase from CDXS last price ($3.17).
Codexis Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $11.00 |
| Last Closing Price | $3.17 | $3.17 | $3.17 |
| Upside/Downside | -100.00% | -100.00% | 247.00% |
In the current month, the average price target of Codexis stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Codexis's last price of $3.17. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 19, 2024 | Benchmark | Positive | Hold | Downgrade |
| Aug 15, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| May 30, 2024 | Cantor Fitzgerald | - | Overweight | Initialise |
| Feb 29, 2024 | Benchmark | - | Positive | Upgrade |
| Jul 14, 2022 | Piper Sandler | Overweight | Overweight | Hold |
| Mar 31, 2022 | Piper Sandler | - | Overweight | Initialise |
Codexis's last stock rating was published by Benchmark on Aug 19, 2024. The company Downgrade its CDXS rating from "Positive" to "Hold".
Codexis Financial Forecast
Codexis Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $9.28M | $21.32M | $12.98M | $30.38M | $34.47M | $38.41M | $35.34M | $24.50M | $36.77M | $25.45M | $18.03M | $21.03M | $18.39M | $14.97M | $14.67M | $18.65M | $21.91M | $12.32M | $15.58M | $14.04M | $7.97M |
| Avg Forecast | $19.51M | $16.95M | $14.81M | $13.69M | $27.91M | $11.85M | $7.82M | $13.31M | $19.90M | $10.03M | $19.83M | $14.09M | $28.93M | $30.94M | $38.11M | $28.59M | $23.20M | $28.59M | $18.30M | $14.42M | $20.88M | $15.91M | $11.24M | $12.73M | $21.38M | $16.75M | $14.06M | $14.68M | $16.85M | $7.09M |
| High Forecast | $25.05M | $21.76M | $19.01M | $17.57M | $35.83M | $14.57M | $10.04M | $17.08M | $20.56M | $12.88M | $25.46M | $18.09M | $37.14M | $39.72M | $49.68M | $37.27M | $30.25M | $37.27M | $23.85M | $18.80M | $27.22M | $20.74M | $14.65M | $16.60M | $27.87M | $21.84M | $18.33M | $19.14M | $20.22M | $8.50M |
| Low Forecast | $18.13M | $15.75M | $13.76M | $12.72M | $25.93M | $10.69M | $7.27M | $12.36M | $19.23M | $9.32M | $18.42M | $13.09M | $26.88M | $28.74M | $33.86M | $25.40M | $20.62M | $25.40M | $16.26M | $12.81M | $18.55M | $14.13M | $9.98M | $11.31M | $19.00M | $14.88M | $12.49M | $13.04M | $13.48M | $5.67M |
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 9 | 15 | 9 | 9 | 16 | 8 | 10 | 16 | 18 | 7 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.92% | 1.08% | 0.92% | 1.05% | 1.11% | 1.01% | 1.24% | 1.06% | 1.29% | 1.39% | 1.25% | 1.01% | 1.16% | 1.33% | 1.15% | 0.87% | 1.31% | 0.88% | 1.06% | 0.83% | 1.13% |
Codexis's average Quarter revenue forecast for Dec 23 based on 4 analysts is $19.90M, with a low forecast of $19.23M, and a high forecast of $20.56M. CDXS's average Quarter revenue forecast represents a 114.52% increase compared to the company's last Quarter revenue of $9.28M (Sep 23).
Codexis EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 9 | 15 | 9 | 9 | 16 | 8 | 10 | 16 | 18 | 7 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-32.06M | $-12.63M | $-23.52M | $-6.92M | $-8.02M | $-2.61M | $-8.39M | $-8.26M | $3.83M | $-2.67M | $-7.58M | $-2.68M | $-4.91M | $-4.87M | $-6.25M | $936.00K | $1.99M | $-5.17M | $-3.82M | $-4.39M | $-7.09M |
| Avg Forecast | $-6.21M | $-5.40M | $-4.72M | $-4.36M | $-8.89M | $-3.77M | $-2.49M | $-11.24M | $-6.34M | $-3.19M | $-6.31M | $-10.22M | $-9.21M | $10.08M | $-12.13M | $-10.93M | $-7.39M | $-9.10M | $-5.83M | $-10.09M | $-6.65M | $-5.07M | $-3.58M | $-7.39M | $-6.81M | $-5.33M | $-4.48M | $-4.46M | $-5.20M | $-6.22M |
| High Forecast | $-5.77M | $-5.01M | $-4.38M | $-4.05M | $-8.26M | $-3.40M | $-2.31M | $-8.99M | $-6.12M | $-2.97M | $-5.87M | $-8.17M | $-8.56M | $12.09M | $-10.78M | $-8.74M | $-6.57M | $-8.09M | $-5.18M | $-8.07M | $-5.91M | $-4.50M | $-3.18M | $-5.91M | $-6.05M | $-4.74M | $-3.98M | $-3.57M | $-4.16M | $-4.98M |
| Low Forecast | $-7.98M | $-6.93M | $-6.05M | $-5.60M | $-11.41M | $-4.64M | $-3.20M | $-13.49M | $-6.55M | $-4.10M | $-8.11M | $-12.26M | $-11.83M | $8.06M | $-15.82M | $-13.11M | $-9.63M | $-11.87M | $-7.60M | $-12.10M | $-8.67M | $-6.60M | $-4.66M | $-8.86M | $-8.88M | $-6.95M | $-5.84M | $-5.35M | $-6.24M | $-7.47M |
| Surprise % | - | - | - | - | - | - | - | - | - | 10.04% | 2.00% | 2.30% | 0.75% | -0.80% | 0.22% | 0.77% | 1.12% | -0.42% | 0.46% | 0.75% | 0.40% | 0.97% | 1.36% | 0.85% | -0.14% | -0.37% | 1.15% | 0.86% | 0.84% | 1.14% |
2 analysts predict CDXS's average Quarter EBITDA for Dec 21 to be $-7.39M, with a high of $-6.57M and a low of $-9.63M. This is -292.73% lower than Codexis's previous annual EBITDA (Sep 21) of $3.83M.
Codexis Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 9 | 15 | 9 | 9 | 16 | 8 | 10 | 16 | 18 | 7 |
| Net Income | - | - | - | - | - | - | - | - | - | $-34.91M | $-11.52M | $-22.62M | $-12.61M | $-9.99M | $-2.64M | $-8.36M | $-10.19M | $2.24M | $-4.26M | $-9.07M | $-3.92M | $-6.09M | $-6.34M | $-7.65M | $-635.00K | $343.00K | $-6.51M | $-5.14M | $-4.69M | $-7.46M |
| Avg Forecast | $-12.81M | $-13.09M | $-13.65M | $-13.79M | $-2.99M | $-16.63M | $-18.56M | $-11.31M | $-8.75M | $-22.82M | $-15.04M | $-10.28M | $-15.92M | $5.96M | $-9.76M | $-10.99M | $-14.08M | $-6.53M | $-12.23M | $-11.79M | $-6.54M | $-5.98M | $-11.49M | $-8.67M | $1.76M | $-4.08M | $-5.49M | $-5.65M | $-5.48M | $-6.53M |
| High Forecast | $-11.63M | $-11.88M | $-12.39M | $-12.52M | $-2.72M | $-15.96M | $-16.85M | $-9.05M | $-1.64M | $-20.72M | $-13.66M | $-8.22M | $-14.45M | $7.15M | $-8.35M | $-8.80M | $-12.03M | $-5.59M | $-10.46M | $-9.43M | $-5.60M | $-5.11M | $-9.83M | $-6.94M | $2.45M | $-3.49M | $-4.69M | $-4.52M | $-4.38M | $-5.22M |
| Low Forecast | $-17.53M | $-17.92M | $-18.69M | $-18.88M | $-4.09M | $-17.29M | $-25.41M | $-13.57M | $-16.95M | $-31.24M | $-20.59M | $-12.34M | $-21.80M | $4.77M | $-13.62M | $-13.19M | $-19.63M | $-9.11M | $-17.05M | $-14.15M | $-9.13M | $-8.34M | $-16.03M | $-10.41M | $1.50M | $-5.69M | $-7.66M | $-6.78M | $-6.57M | $-7.83M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.53% | 0.77% | 2.20% | 0.79% | -1.68% | 0.27% | 0.76% | 0.72% | -0.34% | 0.35% | 0.77% | 0.60% | 1.02% | 0.55% | 0.88% | -0.36% | -0.08% | 1.19% | 0.91% | 0.86% | 1.14% |
Codexis's average Quarter net income forecast for Dec 21 is $-14.08M, with a range of $-19.63M to $-12.03M. CDXS's average Quarter net income forecast represents a -727.24% decrease compared to the company's last Quarter net income of $2.24M (Sep 21).
Codexis SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 9 | 15 | 9 | 9 | 16 | 8 | 10 | 16 | 18 | 7 |
| SG&A | - | - | - | - | - | - | - | - | - | $12.30M | $13.37M | $15.40M | $12.31M | $13.50M | $10.66M | $15.71M | $11.72M | $13.41M | $12.79M | $11.40M | $8.74M | $8.80M | $8.52M | $8.99M | $7.32M | $7.87M | $7.90M | $8.41M | $7.75M | $6.61M |
| Avg Forecast | $9.74M | $8.46M | $7.39M | $6.83M | $13.93M | $5.91M | $3.90M | $6.64M | $9.93M | $5.01M | $9.90M | $7.03M | $14.44M | $15.44M | $19.02M | $20.66M | $11.58M | $14.27M | $9.13M | $7.20M | $10.42M | $7.94M | $5.61M | $-2.24M | $10.67M | $8.36M | $7.02M | $438.90K | $662.67K | $671.13K |
| High Forecast | $12.50M | $10.86M | $9.49M | $8.77M | $17.88M | $7.27M | $5.01M | $8.53M | $10.26M | $6.43M | $12.71M | $9.03M | $18.54M | $19.82M | $24.79M | $24.80M | $15.10M | $18.60M | $11.90M | $9.38M | $13.59M | $10.35M | $7.31M | $-1.79M | $13.91M | $10.90M | $9.15M | $526.68K | $795.20K | $805.35K |
| Low Forecast | $9.05M | $7.86M | $6.87M | $6.35M | $12.94M | $5.34M | $3.63M | $6.17M | $9.60M | $4.65M | $9.20M | $6.53M | $13.42M | $14.35M | $16.90M | $16.53M | $10.29M | $12.68M | $8.11M | $6.39M | $9.26M | $7.05M | $4.98M | $-2.69M | $9.48M | $7.43M | $6.24M | $351.12K | $530.13K | $536.90K |
| Surprise % | - | - | - | - | - | - | - | - | - | 2.46% | 1.35% | 2.19% | 0.85% | 0.87% | 0.56% | 0.76% | 1.01% | 0.94% | 1.40% | 1.58% | 0.84% | 1.11% | 1.52% | -4.01% | 0.69% | 0.94% | 1.13% | 19.17% | 11.69% | 9.84% |
Codexis's average Quarter SG&A projection for Dec 23 is $9.93M, based on 4 Wall Street analysts, with a range of $9.60M to $10.26M. The forecast indicates a -19.26% fall compared to CDXS last annual SG&A of $12.30M (Sep 23).
Codexis EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 9 | 15 | 9 | 9 | 16 | 8 | 10 | 16 | 18 | 7 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.50 | $-0.17 | $-0.34 | $-0.19 | $-0.15 | $-0.04 | $-0.13 | $-0.16 | $0.03 | $-0.07 | $-0.14 | $-0.06 | $-0.10 | $-0.11 | $-0.13 | $-0.01 | $0.01 | $-0.12 | $-0.09 | $-0.10 | $-0.18 |
| Avg Forecast | $-0.18 | $-0.19 | $-0.19 | $-0.20 | $-0.04 | $-0.24 | $-0.26 | $-0.18 | $-0.12 | $-0.32 | $-0.21 | $-0.31 | $-0.23 | $-0.19 | $-0.14 | $-0.19 | $-0.20 | $-0.09 | $-0.17 | $-0.20 | $-0.09 | $-0.09 | $-0.16 | $-0.13 | $0.03 | $-0.06 | $-0.08 | $-0.07 | $-0.14 | $-0.14 |
| High Forecast | $-0.17 | $-0.17 | $-0.18 | $-0.18 | $-0.04 | $-0.23 | $-0.24 | $-0.16 | $-0.02 | $-0.29 | $-0.19 | $-0.28 | $-0.21 | $-0.17 | $-0.12 | $-0.16 | $-0.17 | $-0.08 | $-0.15 | $-0.17 | $-0.08 | $-0.07 | $-0.14 | $-0.11 | $0.03 | $-0.05 | $-0.07 | $-0.06 | $-0.11 | $-0.11 |
| Low Forecast | $-0.25 | $-0.25 | $-0.27 | $-0.27 | $-0.06 | $-0.25 | $-0.36 | $-0.25 | $-0.24 | $-0.44 | $-0.29 | $-0.42 | $-0.31 | $-0.25 | $-0.19 | $-0.26 | $-0.28 | $-0.13 | $-0.24 | $-0.28 | $-0.13 | $-0.12 | $-0.23 | $-0.18 | $0.02 | $-0.08 | $-0.11 | $-0.10 | $-0.17 | $-0.17 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.54% | 0.80% | 1.10% | 0.84% | 0.81% | 0.29% | 0.70% | 0.80% | -0.32% | 0.40% | 0.69% | 0.65% | 1.18% | 0.67% | 1.00% | -0.40% | -0.17% | 1.54% | 1.20% | 0.71% | 1.29% |
According to 2 Wall Street analysts, Codexis's projected average Quarter EPS for Dec 21 is $-0.20, with a low estimate of $-0.28 and a high estimate of $-0.17. This represents a -766.67% decrease compared to CDXS previous annual EPS of $0.03 (Sep 21).
Codexis Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| KZR | Kezar Life Sciences | $0.58 | $17.50 | 2917.24% | Buy |
| IPSC | Century Therapeutics | $1.66 | $20.00 | 1104.82% | Buy |
| NGM | NGM Biopharmaceuticals | $1.54 | $16.50 | 971.43% | Buy |
| LYEL | Lyell Immunopharma | $1.39 | $9.50 | 583.45% | Hold |
| NKTX | Nkarta | $5.39 | $21.60 | 300.74% | Buy |
| CDXS | Codexis | $3.16 | $11.00 | 248.10% | Buy |
| STTK | Shattuck Labs | $3.75 | $12.00 | 220.00% | Buy |
| MLYS | Mineralys Therapeutics | $11.98 | $30.00 | 150.42% | Buy |
| NUVB | Nuvation Bio | $3.07 | $6.75 | 119.87% | Buy |
| CGEM | Cullinan Oncology | $17.24 | $32.00 | 85.61% | Buy |
| FHTX | Foghorn Therapeutics | $9.84 | $18.00 | 82.93% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $43.77 | $52.17 | 19.19% | Buy |
| NRIX | Nurix Therapeutics | $24.83 | $27.57 | 11.04% | Buy |
| KYMR | Kymera Therapeutics | $47.30 | $51.10 | 8.03% | Buy |
CDXS Forecast FAQ
Is Codexis a good buy?
Yes, according to 3 Wall Street analysts, Codexis (CDXS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 66.67% of CDXS's total ratings.
What is CDXS's price target?
Codexis (CDXS) average price target is $11 with a range of $11 to $11, implying a 247.00% from its last price of $3.17. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Codexis stock go up soon?
According to Wall Street analysts' prediction for CDXS stock, the company can go up by 247.00% (from the last price of $3.17 to the average price target of $11), up by 247.00% based on the highest stock price target, and up by 247.00% based on the lowest stock price target.
Can Codexis stock reach $5?
CDXS's average twelve months analyst stock price target of $11 supports the claim that Codexis can reach $5 in the near future.
What are Codexis's analysts' financial forecasts?
Codexis's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $60.89M (high $77.53M, low $56.25M), average EBITDA is $-26.391M (high $-22.966M, low $-32.735M), average net income is $-49.487M (high $-44.572M, low $-60.365M), average SG&A $30.39M (high $38.69M, low $28.07M), and average EPS is $-0.722 (high $-0.668, low $-0.911). CDXS's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $64.96M (high $83.39M, low $60.35M), average EBITDA is $-20.685M (high $-19.218M, low $-26.555M), average net income is $-53.345M (high $-48.425M, low $-73.025M), average SG&A $32.42M (high $41.62M, low $30.12M), and average EPS is $-0.758 (high $-0.688, low $-1.038).
Did the CDXS's actual financial results beat the analysts' financial forecasts?
Based on Codexis's last annual report (Dec 2022), the company's revenue was $138.59M, beating the average analysts forecast of $126.56M by 9.50%. Apple's EBITDA was $-28.547M, beating the average prediction of $-22.198M by 28.60%. The company's net income was $-33.592M, beating the average estimation of $-30.721M by 9.35%. Apple's SG&A was $52.17M, missing the average forecast of $69.56M by -25.00%. Lastly, the company's EPS was $-0.51, missing the average prediction of $-0.738 by -30.85%. In terms of the last quarterly report (Sep 2023), Codexis's revenue was $9.28M, missing the average analysts' forecast of $10.03M by -7.52%. The company's EBITDA was $-32.06M, beating the average prediction of $-3.194M by 903.64%. Codexis's net income was $-34.908M, beating the average estimation of $-22.822M by 52.96%. The company's SG&A was $12.3M, beating the average forecast of $5.01M by 145.71%. Lastly, the company's EPS was $-0.5, beating the average prediction of $-0.324 by 54.18%